EMFAT
ADMS

Emerald Mutual Fund Advisers Trust’s Adamas Pharmaceuticals ADMS Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-307,723
Closed -$1.27M – 350
2020
Q3 		$1.27M Sell
307,723
-314,326
-51% -$1.22M 0.06% 156
2020
Q2 		$1.59M Buy
622,049
+25,000
+4% +$73.5K 0.08% 145
2020
Q1 		$1.73M Buy
597,049
+40,022
+7% +$179K 0.11% 140
2019
Q4 		$2.11M Sell
557,027
-51,992
-9% -$249K 0.09% 171
2019
Q3 		$3.12M Sell
609,019
-7,645
-1% -$47.2K 0.14% 157
2019
Q2 		$3.82M Buy
616,664
+51,345
+9% +$295K 0.15% 150
2019
Q1 		$4.02M Hold
565,319
– – 0.16% 158
2018
Q4 		$4.83M Sell
565,319
-61,422
-10% -$799K 0.23% 140
2018
Q3 		$12.5M Buy
626,741
+76,387
+14% +$1.79M 0.42% 96
2018
Q2 		$14.2M Buy
550,354
+17,877
+3% +$495K 0.51% 79
2018
Q1 		$12.7M Buy
532,477
+2,540
+0.5% +$80.1K 0.5% 70
2017
Q4 		$18M Hold
529,937
– – 0.71% 46
2017
Q3 		$11.2M Sell
529,937
-41,852
-7% -$767K 0.47% 76
2017
Q2 		$10M Hold
571,789
– – 0.44% 81
2017
Q1 		$10M Hold
571,789
– – 0.46% 75
2016
Q4 		$9.66M Hold
571,789
– – 0.46% 77
2016
Q3 		$9.38M Buy
571,789
+11,910
+2% +$181K 0.48% 84
2016
Q2 		$8.48M Buy
559,879
+21,301
+4% +$351K 0.48% 82
2016
Q1 		$7.79M Buy
538,578
+86,895
+19% +$1.46M 0.44% 91
2015
Q4 		$12.8M Buy
451,683
+89,371
+25% +$1.5M 0.68% 59
2015
Q3 		$6.07M Buy
362,312
+45,622
+14% +$1.04M 0.4% 94
2015
Q2 		$8.3M Sell
316,690
-9,840
-3% -$191K 0.64% 61
2015
Q1 		$5.72M Buy
326,530
+114,656
+54% +$1.96M 0.47% 81
2014
Q4 		$3.68M Buy
211,874
+38,654
+22% +$586K 0.32% 97
2014
Q3 		$3.23M Buy
173,220
+66,999
+63% +$1.15M 0.31% 103
2014
Q2 		$1.94M Buy
+106,221
New +$1.9M 0.18% 125

Other funds holding ADMS

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's ADMS Position: Q4 2020 in Review

Emerald Mutual Fund Advisers Trust sold out of Adamas Pharmaceuticals (ADMS) in Q4 2020, closing a stake of 307,723 shares — an estimated $1.27M sold.

Emerald Mutual Fund Advisers Trust first reported a position in ADMS in Q2 2014 and held it in 26 quarters. The position peaked at $18M in Q4 2017. 65 funds tracked by Wall St. Rank hold ADMS as of Q4 2020.

  • Emerald Mutual Fund Advisers Trust reported no remaining Adamas Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 307,723 Adamas Pharmaceuticals shares in Q4 2020, an estimated $1.27M.
  • Emerald Mutual Fund Advisers Trust first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 26 quarters.
  • Emerald Mutual Fund Advisers Trust's Adamas Pharmaceuticals position peaked at $18M in Q4 2017.
  • 65 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2020.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q4 2020, filed 29 Jan 2021.